Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 128 results for epilepsies

  1. Further research should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction in concomitant medication and hospital admissions.

    Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction...

  2. Contraception: advice for people taking anti-seizure medication (IND78)

    This indicator covers the percentage of women under the age of 55 years who are taking antiseizure medications who have a record of information and counselling about contraception, conception and pregnancy in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM03

  3. AEDs and pregnancy: What is the malformation rate and longer term neurodevelopmental outcome of children born to mothers who have taken AEDs during pregnancy?

    cognitive) and behavioural outcomes in children born to women and girls with epilepsy (these should be undertaken on a long-term basis...

  4. Medicines associated with dependence or withdrawal symptoms. Patient decision aid summary version on should I stop my benzodiazepine or z-drug?

    or problems sleeping. Benzos can be used for other conditions, such as epilepsy. Talk to your healthcare professional if this applies to...

  5. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

  6. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

  7. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.

  8. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.

  9. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  10. Guidance and quality standards in consultation

    See a complete list of all our guidance and quality standards currently open for consultation

  11. Why address health inequalities?

    Health inequalities can be experienced by people grouped by a range of different factors.

  12. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

    This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.

  13. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

  14. What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults?

    recommendationsThe only cannabis-based medicinal product available for the treatment of epilepsy is epidyolex, which is licensed...

  15. Violent and aggressive behaviours in people with mental health problems (QS154)

    This quality standard covers short-term prevention and management of violent and physically threatening behaviour among adults, children and young people with a mental health problem. It applies to settings where mental health, health and social care services are provided. This includes community settings and care received at home. It describes high-quality care in priority areas for improvement.